MMV183

TropIQ
Asexual blood stages
Transmission reduction

MMV183

Translational
-
Preclinical
Product vision
  • Uncomplicated malaria treatment and resistance management 
MOA
  • Novel mechanism - inhibition of acetylCoA synthetase
Key features

  • Predicted 100 mg single-dose in man

  • Transmission-blocking activity
  • No pre-existing resistance, no resistance in vitro
Challenges
  • Synthetic route optimization
  • Low melting point compound with poor yield from final recrystallisation step
Status
  • Nonclinical development – Good Laboratory Practice (GLP) general toxicology complete
Next milestone
  • Good Manufacturing Practice (GMP) drug substance synthesis
Previously
  • Discovery collaboration with TropIQ
Project Director
  • Dr Andrew Slade